Literature DB >> 21951647

Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.

Maxine Sun1, Firas Abdollah, Jan Schmitges, Marco Bianchi, Zhe Tian, Shahrokh F Shariat, Kevin Zorn, Daniel Pharand, Hugues Widmer, Markus Graefen, Francesco Montorsi, Paul Perrotte, Pierre I Karakiewicz.   

Abstract

UNLABELLED: Study Type - Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? While cytoreductive nephrectomy is associated with a survival benefit in the context of metastatic renal cell carcinoma, the rates of morbidity and perioperative mortality remain non-negligible. For example, perioperative mortality may be as high as 21% in elderly patients. The study shows that perioperative death amongst the elderly was substantially lower than what was previously reported from a single institutional report. Nonetheless, postoperative adverse outcomes were non-negligible in elderly patients relative to their younger counterparts. In consequence, these rates should be discussed at informed consent and a rigorous patient selection remains essential.
OBJECTIVE: • To examine the rate of perioperative mortality (PM), and other adverse outcomes in 'elderly' patients treated with cytoreductive nephrectomy (CNT).
MATERIAL AND METHODS:Patients who underwent CNT for metastatic renal cell carcinoma were abstracted from the Nationwide Inpatient Sample (1998-2007). 'Elderly' was defined as ≥ 75 years, according to previous definition. • Endpoints consisted of PM, intraoperative and postoperative complications, blood transfusions and length of stay. • We adjusted for the effect of elderly status within five separate logistic regression models. Covariates consisted of comorbidity, race, gender, year of surgery and hospital region.
RESULTS: • Overall, CNT was performed in 504 (15.3%) elderly patients and in 2796 (84.7%) 'younger' patients (<75 years). • The rate of PM was 4.8% in elderly patients vs 1.9% in the younger patients (P < 0.001). Similarly, the rates of blood transfusions (29.8 vs 21.5%), postoperative complications (27.8 vs 22.8%), and prolonged length of stay (≥ 8 days) were higher in the elderly (45.0 vs 32.0%; all P < 0.001). • In multivariable analyses, elderly patients were 2.2-, 1.5-, and 1.6 fold more likely to experience PM, to receive a blood transfusion and to be hospitalized ≥ 8 days than the younger patients.
CONCLUSIONS: • Although the rate of PM was substantially lower than 21%, elderly patients are significantly more likely to die after this type of surgery, to receive a transfusion, and to experience a prolonged length of stay. • These facts and figures should be discussed at informed consent and a rigorous patient selection is essential.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21951647     DOI: 10.1111/j.1464-410X.2011.10569.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival.

Authors:  Brian J Minnillo; William Tabayoyong; John J Francis; Matthew J Maurice; Hui Zhu; Simon Kim; Robert Abouassaly
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

Review 2.  The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.

Authors:  Pierre Bigot; Souhil Lebdai; Alain Ravaud; Abdel Rahmène Azzouzi; Jean-Marie Ferrière; Jean-Jacques Patard; Jean-Christophe Bernhard
Journal:  World J Urol       Date:  2013-03-30       Impact factor: 4.226

Review 3.  Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.

Authors:  Laura-Maria Krabbe; Ahmed Q Haddad; Mary E Westerman; Vitaly Margulis
Journal:  World J Urol       Date:  2014-04-04       Impact factor: 4.226

Review 4.  Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.

Authors:  Stephen H Culp
Journal:  Ther Adv Urol       Date:  2015-10

5.  Trends in the use of cytoreductive nephrectomy in the United States.

Authors:  Che-Kai Tsao; Alexander C Small; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  Clin Genitourin Cancer       Date:  2012-05-30       Impact factor: 2.872

Review 6.  [Renal cell carcinoma in older and geriatric patients].

Authors:  N Wagener
Journal:  Urologe A       Date:  2017-08       Impact factor: 0.639

7.  Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Authors:  Che-kai Tsao; Alexander C Small; Max Kates; Erin L Moshier; Juan P Wisnivesky; Benjamin A Gartrell; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  World J Urol       Date:  2012-12-08       Impact factor: 4.226

Review 8.  Recent advances in cancer surgery in older patients.

Authors:  Siri Rostoft; Riccardo A Audisio
Journal:  F1000Res       Date:  2017-07-27

Review 9.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

Review 10.  The role of open radical nephrectomy in contemporary management of renal cell carcinoma.

Authors:  Arveen A Kalapara; Mark Frydenberg
Journal:  Transl Androl Urol       Date:  2020-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.